本帖最后由 老马 于 2012-1-13 21:20 编辑 5 v/ o- @! X6 K1 D: r4 \
p0 S' ]/ d+ C
爱必妥和阿瓦斯丁的比较, O* S. @; G8 o2 m, l& I: F
' y6 _6 ^6 _' `& V4 E" [6 w; |http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
# i: A8 n" m. v9 I6 e
* X; q0 D6 E; }9 @ h0 @
' b# m2 H2 s, xhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
& s( _0 T0 Z0 {( [4 I4 Y==================================================
7 w5 e% D# j# }Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)/ G2 S; M& s" b6 E
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
4 j) \2 @8 W2 IResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.4 u0 r3 @/ a) d# q( h, Y$ w, z$ Y
|